Clinical Trials on Novel H1N1 Influenzal Acute Respiratory Infection

Total 3999 results

ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Seasonal Influenza

United States
Cocrystal Pharma, Inc.
Cocrystal Pharma Australia Pty Ltd.; Linear Clinical Research

Completed

CC-42344 Safety Study in Healthy Participants

Influenza A

Australia
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
ENA Respiratory Pty Ltd

Completed

INNA-051 Influenza Challenge Study

Influenza Prophylaxis

United Kingdom
Visterra, Inc.

Completed

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

Influenza A

United States, Australia, Belarus, Belgium, Bulgaria, Canada, Estonia, France, Georgia, Latvia, Malaysia, New Zealand, Russian Federation, Serbia, Singapore, South Africa, Spain, Thailand, Turkey, Ukraine
Vir Biotechnology, Inc.

Completed

Study of VIR-2482 in Healthy Volunteers

Influenza A

Australia
Intercell USA, Inc.
Department of Health and Human Services

Completed

A/H5N1/LT Dose Ranging Study

Pandemic Influenza

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A

United States, France, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Israel, India, Thailand, New Zealand, Vietnam, Germany, Latvia, Spain, Russian Federation, Turkey, Argentina, Singapore, Brazil, Hungary, Malaysia, Au... and more
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection

Influenza Prophylaxis

Hungary
Fluart Innovative Vaccine Ltd, Hungary

Completed

Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents

Human Influenza
University of Warwick

Completed

Influenza 2020/2021

Influenza Vaccine

United Kingdom
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
GlaxoSmithKline

Completed

Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

Influenza | Influenza Vaccines

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years

Influenza Vaccines

Canada
The University of Texas Health Science Center at...
Sendero Health Plans, Inc.

Unknown

Investigating the Effectiveness of a Seasonal Influenza Vaccination Promotion Campaign for Members of a Non-Profit, Community-Based Health Insurance Plan: 2018-2019

Influenza, Vaccination

United States
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Human Influenza

Kazakhstan
Green Cross Corporation

Unknown

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age

Influenza Vaccine

Korea, Republic of
Hualan Biological Bacterin Co. Ltd.

Completed

Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Influenza A
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010

Seasonal Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza

Italy
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

Influenza Virus

United Kingdom
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011

Seasonal Influenza

Italy
University of Oxford

Completed

A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1

Seasonal Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Ology Bioservices

Completed

Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

Influenza | Pandemic Influenza

Austria
Vaxart

Completed

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum (ICC H1)

Seasonal Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

Seasonal Influenza

Colombia, Mexico, Panama, Philippines
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Novavax
Instituto Mexicano del Seguro Social

Completed

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

Seasonal Influenza

Mexico
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Seasonal Influenza

Italy
University of Pennsylvania
Yale University; Stanford University; Harvard University

Completed

The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates

Seasonal Influenza

United States
Centers for Disease Control, Taiwan
Public Health Bureau,Taoyan County Governmnet, Taiwan; Education Department...

Completed

Evaluation of a School-based Influenza Vaccination Program

Influenza | Influenza Vaccines

Taiwan
HaEmek Medical Center, Israel

Completed

The Effectiveness of Influenza Vaccine Among Health Care Workers in a Hospital Setting.

Influenza Vaccines

Israel
Assistance Publique - Hôpitaux de Paris

Terminated

Influenza Vaccination of Nursing Home Workers.

Influenza Disease

France
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Changchun BCHT Biotechnology Co.
Hu Bei province Center for Disease control and prevention; The Inner Mongolia...

Recruiting

Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine

Influenza Prevention

China
Tan Tock Seng Hospital
Sanofi; A*Star; World Health Organization Collaborating Centre for Reference...

Recruiting

Immunogenicity Trial of 3 Influenza Vaccines

Influenza Vaccination

Singapore
University of Pennsylvania

Recruiting

Study of Immune Responses to Influenza Vaccination

Influenza Vaccination

United States
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
National Institute of Allergy and Infectious Diseases...

Completed

Flublok or Fluzone With Advax-CpG55.2 or AF03

Influenza | Influenza Immunisation

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Denmark, Poland, Spain, Czechia
Vir Biotechnology, Inc.

Terminated

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Influenza A

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Seasonal Influenza

United States
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Seasonal Influenza

Italy
BlueWillow Biologics
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Active, not recruiting

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults (IN-NE-rH5)

Influenza, Pandemic

United States
AB Biotics, SA

Completed

Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination (FLUVAC21)

Influenza Vaccine

Spain

Clinical Trials on Novel H1N1 Influenzal Acute Respiratory Infection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations